tbuckley/cabot-search huggingface dataset:
Systematic review of self‐management interventions for people with eczema
Authors: M.J. Ridd, A.J.L. King, E. Le Roux, A. Waldecker, A.L. Huntley
Journal: British Journal of Dermatology (2017)

Eczema is a common long‐term condition, but inadequate support and information can lead to poor adherence and treatment failure. We have reviewed the international literature of interventions designed to promote self‐management in adults and children with eczema. MEDLINE, MEDLINE in process, Embase, CINAHL and the Global Resource for EczemA Trials database were searched from their inception to August 2016, for randomized controlled trials. Two authors independently applied eligibility criteria, assessed risk of bias for all included studies and extracted data. Twenty studies (3028 participants) conducted in 11 different countries were included. The majority (n =18) were based in secondary care and most (n =16) targeted children with eczema. Reporting of studies, including descriptions of the interventions and the outcomes themselves, was generally poor. Thirteen studies were face‐to‐face educational interventions, five were delivered online and two were studies of written action plans. Follow‐up in most studies (n =12) was short term (up to 12 weeks). Only six trials specified a single primary outcome. There was limited evidence of effectiveness. Only three studies collected and reported outcomes related to cost and just one study undertook any formal cost‐effectiveness analysis. In summary, we have identified a general absence of well‐conducted and well‐reported randomized controlled trials with a strong theoretical basis. Therefore, there is still uncertainty about how best to support self‐management of eczema in a clinically effective and cost‐effective way. Recommendations on design and conduct of future trials are presented.
Abstract 4373: JNK1 participates in the VHL-independent HIF-1α degradation pathway by regulating Hsp90/Hsp70 turnover and the HDAC6-dependent chaperone activity
Authors: Dongyun Zhang, Tongjian Cai, Jingxia Li, Max Costa, Chuanshu Huang
Journal: Cancer Research (2010)

Abstract Nickel has been proved to be a human carcinogen. Hypoxia induced factor-1α (HIF-1α) plays a key role in the pathological processes of cancers. Previous studies have shown that nickel can exert its carcinogenic effects through the induction of HIF-1α accumulation. However, the molecular mechanisms have not been well understood. The c-Jun N-terminal kinase 1 (JNK1) is implicated in several physiological processes, including proliferation, apoptosis and differentiation, which are thought to be involved in several cancer development. JNK1 is also known to regulate the level of Hsp90/Hsp70. Our present study was conducted to investigate the role of JNK1 in the accumulation of HIF-1α induced by nickel. In current studies, we demonstrated that JNK1 is required for such an Hsp-dependent HIF-1α regulation. HIF-1α stabilization was impaired in JNK1−/− cells, and could be rescued by reconstitutional expression of JNK1 in either hypoxia or chemical-mimicked hypoxia conditions. Accordingly, HIF-1-dependent transcriptional activity and its downstream gene's expression were dramatically reduced in JNK1-deficient cells. We further disclosed that in JNK1−/− cells the low expression level of Hsp90/Hsp70 proteins affected the protective roles of these chaperones in maintaining newly synthesized HIF-1α stabilization, and forced expression of Hsp90 or Hsp70 in JNK1−/− cells showed a notable increase in HIF-1α stability compared with that of parental cells. Furthermore, our studies found that defective HDAC6 expression and subsequently increased Hsp90 acetylation could account for the reduction of Hsp90 chaperon activity in JNK1−/− cells. Our studies for the first time disclose a novel function of JNK1 in the modulation of HIF-1ααstabilization under nickel mimicked chemical hypoxia conditions through regulation of Hsp90/Hsp70 expression as well as HDAC6-mediated Hsp90 acetylation modification. This novel function may contribute to JNK1-mediated carcinogenic effects in response to nickel exposure. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4373.
MINK1: The missing link between ROS and its inhibition of Th17 cells
Authors: Gustavo J. Martinez
Journal: The Journal of Experimental Medicine (2017)

In this issue of JEM, Fu et al. (https://doi.org/10.1084/jem.20161120) identified the kinase Mink1 as a novel negative regulator of Th17 cell generation. Mink1, activated by reactive oxygen species (ROS), prevents TGF-β activation of Smad2, therefore limiting Th17 cell differentiation.
Adjuvant and neoadjuvant trastuzumab in combination with vinorelbine for HER2+ breast cancer.
Authors: Khashayar Esfahani, Cristiano Ferrario, Philippe Le, Lawrence C. Panasci
Journal: Journal of Clinical Oncology (2014)

e11585 Background: Growing evidence suggest that even small early stage HER2+ breast cancers (BCs) should be treated with adjuvant chemotherapy to reduce recurrence rates. Some patients are not candidate for anthracycline-based chemotherapy, given their frailty or preference to avoid chemotherapy-related toxicities. Phase III randomized trials of Herceptin with vinorelbine (HV) in metastatic breast cancer patients have shown good response rates and favorable toxicity profiles of HV over taxane-based regimens. We herein report our experience with patients receiving HV at our institution. Methods: Retrospective data was collected on all stage I-III patients receiving HV as the only chemotherapy regimen in the adjuvant and neoadjuvant settings. Most patients received HV on a weekly basis (one week off for V every 3–4 weeks) for 6 months, followed by 6 more months of H. Results: Between 2003 and 2012, 46 HER2+ patients were identified (adjuvant: n=36; neoadjuvant: n=10). Median age was 65. 81% of patients in the adjuvant arm had Stage I disease, and 61% of all patients were ER/PR+. 3 patients in the neoadjuvant arm had a complete pathological response. All patients treated in the neo-adjuvant arm have remained disease-free. Only one patient had a local recurrence following a short course of HV (3 months). She was retreated with the same regimen following surgical resection, and has remained disease-free since. Overall survival and disease-free survival were 94% and 98% respectively at 5 years of median follow-up. One patient with significant medical comorbidities died of febrile neutropenia induced sepsis, and two others died of comorbidities unrelated to their cancer or treatment. Grade 3-4 adverse effects included neutropenia (22%), febrile neutropenia (8%), fatigue and anemia (2% each). During therapy, 6 patients had an asymptomatic 10–20% drop in the LVEF (Grade 1), with complete recovery on follow-up MUGA scans. Conclusions: HV is a reasonable alternative to standard adjuvant chemotherapy for patients with non-metastatic breast cancer that are not candidates for standard chemotherapy. Further prospective data is required to establish the role of HV in stage I HER2+ BC, for which no standard treatment is defined.
Dexpramipexole As a Steroid-Sparing Agent in Hypereosinophilic Syndromes (HES): An Open-Label Proof-of-Concept Study
Authors: Sandhya R. Panch, Michael Bozik, Thomas Brown, Ulrike Demarco, Jamie Hahn, Alexander Komarov, Tamika Magee, Michelle Makiya, Calman Prussin, Armando Signore, Mary Sullivan, Lauren Wetzler, Cynthia E. Dunbar, Steven Dworetzky, Irina Maric, Amy D Klion
Journal: Blood (2016)
Erratum: KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia
Authors: R Willemze, C A Rodrigues, M Labopin, G Sanz, G Michel, G Socié, B Rio, A Sirvent, M Renaud, L Madero, M Mohty, C Ferra, F Garnier, P Loiseau, J Garcia, L Lecchi, G Kögler, Y Beguin, C Navarrete, T Devos, I Ionescu, K Boudjedir, A-L Herr, E Gluckman, V Rocha
Journal: Leukemia (2009)
Divergent Modes of Tumor Evolution Underlie Histological Transformation and Early Progression of Follicular Lymphoma
Authors: Fong Chun Chan, Robert Kridel, Anja Mottok, Merrill Boyle, Pedro Farinha, King Tan, Barbara Meissner, Ali Bashashati, Andrew McPherson, Andrew Roth, Karey Shumansky, Damian Yap, Susana Ben-Neriah, Jamie Rosner, Maia A. Smith, Cydney Nielsen, Adele Telenius, Daisuke Ennishi, Andrew J. Mungall, Richard Moore, Ryan D. Morin, Nathalie A. Johnson, Laurie H Sehn, Joseph M. Connors, David W Scott, Christian Steidl, Marco A. Marra, Randy D Gascoyne, Sohrab P. Shah
Journal: Blood (2016)
Communicating Context in Quality Improvement Reports
Authors: Ralph Gonzales, Christy Boscardin, Andrew Auerbach
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Effects of diet and antihypertensive therapy on creatinine clearance and serum creatinine concentration in the Modification of Diet in Renal Disease Study.
Journal: Journal of the American Society of Nephrology (1996)

Log in or Register Subscribe to journalSubscribe Get new issue alertsGet alerts Enter your Email address: Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. Subscribe to eTOC Secondary Logo Journal Logo All Articles Images Videos Podcasts Blogs Advanced Search Toggle navigation Subscribe Register Login Articles Current IssuePublished Ahead of Print Subject CollectionsPodcastsArchives Authors Submit to JASNInformation for Authors Journal Info About JASNEditorial TeamEditorial FellowsEditorial Fellowship ApplicationJASN ImpactJASN Recognizes More AlertsAdvertisingSubscriptionsReprints All Articles Images Videos Podcasts Blogs Advanced Search
Management of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) - Data from the Spanish PNH Registry
Authors: Silvia De La Iglesia Iñigo, Cristina Notario McDonell, Anna Gaya Valls, María Teresa Cedena Romero, María Isabel Gómez Roncero, Beatriz Arrizabalaga Amunchastegui, Carmen Monteserin Monteserin, Esperanza Lavilla Rubira, Ana María Villegas Martínez
Journal: Blood (2016)
Feasibility and Efficacy of Dose Adjusted Melphalan - Prednisone - Bortezomib (MPV) in Elderly Patients ≥ 75 Years of Age with Newly Diagnosed Multiple Myeloma; the Non-Randomised Phase II HOVON 123 Study
Authors: Sonja Zweegman, Mark-David Levin, Saskia K. Klein, Esther G.M. De Waal, Corien M. Eeltink, Paula F. Ypma, Amanda C. Dijk, Matthijs Westerman, Wendy Deenik, Bea Tanis, Monique S. Slee-Valentijn, Monique Minnema, Heleen Visser-Wisselaar, Claudia Stege, Niels W.C.J. van de Donk, Kazem Nasserinejad, Pieter Sonneveld
Journal: Blood (2016)
"Clinical analysis of 76 patients pathologically diagnosed with pulmonary cryptococcosis." Yuan Zhang, Nan Li, Yuxuan Zhang, Huiping Li, Xueyuan Chen, Shanmei Wang, Xia Zhang, Rongxuan Zhang, Jinfu Xu, Jingyun Shi and Rex C. Yung. Eur Respir J 2012; 40: 1191-1200.
Authors: Yuan Zhang, Nan Li, Yuxuan Zhang, Huiping Li, Xueyuan Chen, Shanmei Wang, Xia Zhang, Rongxuan Zhang #, Jingyun Shi, Rex Yung
Journal: European Respiratory Journal (2012)
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Authors: Rebecca A. Gardner, Olivia Finney, Colleen Annesley, Hannah Brakke, Corinne Summers, Kasey Leger, Marie Bleakley, Christopher Brown, Stephanie Mgebroff, Karen S. Kelly-Spratt, Virginia Hoglund, Catherine Lindgren, Assaf P. Oron, Daniel Li, Stanley R. Riddell, Julie R. Park, Michael C. Jensen
Journal: Blood (2017)
A Highly Predictive Risk Model for Pacemaker Implantation After TAVR
Authors: Yoshio Maeno, Yigal Abramowitz, Hiroyuki Kawamori, Yoshio Kazuno, Shunsuke Kubo, Nobuyuki Takahashi, Geeteshwar Mangat, Kazuaki Okuyama, Mohammad Kashif, Tarun Chakravarty, Mamoo Nakamura, Wen Cheng, John Friedman, Daniel Berman, Raj R. Makkar, Hasan Jilaihawi
Journal: JACC. Cardiovascular imaging (2017)
Improving motor imagery BCI with user response to feedback
Authors: Mahta Mousavi, Adam S. Koerner, Qiong Zhang, Eunho Noh, Virginia R. de Sa
Journal: Brain-Computer Interfaces (2017)

In brain-computer interface (BCI) systems, the non-stationarity of brain signals is known to be a challenge for training robust classifiers as other brain processes produce signals that coincide with those resulting from the desired brain activity. One source of interference is the user's cognitive response to the provided BCI feedback. In the case of motor imagery paradigms, this feedback can for instance be a cursor moving on the screen. The response to such feedback has been shown in general to be a source of noise that can add to the non-stationarity of the brain signal; however, in this work, we show that the user's brain response to this feedback can be used to improve the BCI performance. We first show in a motor imagery task that the user's brain responds to the direction of cursor movement, which is different for the cursor moving towards or away from the target (i.e. BCI feedback), and this feedback-related information is present in frequency bands similar to those used in motor imagery. Next, we propose a classifier that combines the user response to feedback together with the motor imagery signal itself, and show that this combined classifier can significantly outperform a conventional motor imagery classifier. Our results show an average of 11% and up to 22% improvement in classification accuracy across 10 participants.
Negative Psychosis Prevention Trials—Reply
Authors: Patrick D. McGorry, Barnaby Nelson, Paul Amminger
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Variability in Chromatin Architecture and Associated DNA Repair at Genomic Positions Containing Somatic Mutations
Authors: Byungho Lim, Jihyeob Mun, Yong Sung Kim, Seon-Young Kim
Journal: Cancer Research (2017)

Abstract Dynamic chromatin structures result in differential chemical reactivity to mutational processes throughout the genome. To identify chromatin features responsible for mutagenesis, we compared chromatin architecture around single-nucleotide variants (SNV), insertion/deletions (indels), and their context-matched, nonmutated positions. We found epigenetic differences between genomic regions containing missense SNVs and those containing frameshift indels across multiple cancer types. Levels of active histone marks were higher around frameshift indels than around missense SNV, whereas repressive histone marks exhibited the reverse trend. Accumulation of repressive histone marks and nucleosomes distinguished mutated positions (both SNV and indels) from the context-matched, nonmutated positions, whereas active marks were associated with substitution- and cancer type–specific mutagenesis. We also explained mutagenesis based on genome maintenance mechanisms, including nucleotide excision repair (NER), mismatch repair (MMR), and DNA polymerase epsilon (POLE). Regional NER variation correlated strongly with chromatin features; NER machineries exhibited shifted or depleted binding around SNV, resulting in decreased NER at mutation positions, especially at sites of recurrent mutations. MMR-deficient tumors selectively acquired SNV in regions with high active histone marks, especially H3K36me3, whereas POLE-deficient tumors selectively acquired indels and SNV in regions with low active histone marks. These findings demonstrate the importance of fine-scaled chromatin structures and associated DNA repair mechanisms in mutagenesis. Cancer Res; 77(11); 2822–33. ©2017 AACR.
Association Between the Hematopoietic Cell Transplantation-Specific Comorbidity Index (CI) and Non-Relapse Mortality (NRM) After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1).
Authors: Mohamad Mohty, Myriam Labopin, Nadezda Basara, Jan J. Cornelissen, Reza Tabrizi, Claes Malm, Jose Antonio Pérez Simón, Arnon Nagler, Nicolaus Kroger, Bernard Rio, Rodrigo Martino, Matthias Eder, Karin Bilger, Donald W. Bunjes, Gérard Socié, Didier Blaise, Emmanuelle Polge, Vanderson Rocha
Journal: Blood (2009)
Brief Report: Blockade of TANK‐Binding Kinase 1/IKKɛ Inhibits Mutant Stimulator of Interferon Genes (STING)–Mediated Inflammatory Responses in Human Peripheral Blood Mononuclear Cells
Authors: Marie‐Louise Frémond, Carolina Uggenti, Lien Van Eyck, Isabelle Melki, Vincent Bondet, Naoki Kitabayashi, Christina Hertel, Adrian Hayday, Bénédicte Neven, Yoann Rose, Darragh Duffy, Yanick J. Crow, Mathieu P. Rodero
Journal: Arthritis & Rheumatology (2017)

Objective Gain‐of‐function mutations in TMEM173 , encoding the stimulator of interferon (IFN) genes (STING) protein, underlie a novel type I interferonopathy that is minimally responsive to conventional immunosuppressive therapies and associated with high frequency of childhood morbidity and mortality. STING gain‐of‐function causes constitutive oversecretion of IFN. This study was undertaken to determine the effects of a TANK‐binding kinase 1 (TBK‐1)/IKKɛ inhibitor (BX795) on secretion and signaling of IFN in primary peripheral blood mononuclear cells (PBMCs) from patients with mutations in STING. Methods PBMCs from 4 patients with STING‐associated disease were treated with BX795. The effect of BX795 on IFN pathways was assessed by Western blotting and an IFNβ reporter assay, as well as by quantification of IFNα in cell lysates, staining for STAT‐1 phosphorylation, and measurement of IFN‐stimulated gene (ISG) messenger RNA (mRNA) expression. Results Treatment of PBMCs with BX795 inhibited the phosphorylation of IFN regulatory factor 3 and IFNβ promoter activity induced in HEK 293T cells by cyclic GMP‐AMP or by genetic activation of STING. In vitro exposure to BX795 inhibited IFNα production in PBMCs of patients with STING‐associated disease without affecting cell survival. In addition, BX795 decreased STAT‐1 phosphorylation and ISG mRNA expression independent of IFNα blockade. Conclusion These findings demonstrate the effect of BX795 on reducing type I IFN production and IFN signaling in cells from patients with gain‐of‐function mutations in STING. A combined inhibition of TBK‐1 and IKKɛ therefore holds potential for the treatment of patients carrying STING mutations, and may also be relevant in other type I interferonopathies.
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
Authors: Kenneth C. Anderson, Daniel Auclair, Gary J. Kelloff, Caroline C. Sigman, Hervé Avet-Loiseau, Ann T. Farrell, Nicole J. Gormley, Shaji K. Kumar, Ola Landgren, Nikhil C. Munshi, Michele Cavo, Faith E. Davies, Alessandra Di Bacco, Jennifer S. Dickey, Steven I. Gutman, Howard R. Higley, Mohamad A. Hussein, J. Milburn Jessup, Ilan R. Kirsch, Richard F. Little, Robert D. Loberg, Jens G. Lohr, Lata Mukundan, James L. Omel, Trevor J. Pugh, Gregory H. Reaman, Michael D. Robbins, A. Kate Sasser, Nancy Valente, Elena Zamagni
Journal: Clinical Cancer Research (2017)

Treatment of myeloma has benefited from the introduction of more effective and better tolerated agents, improvements in supportive care, better understanding of disease biology, revision of diagnostic criteria, and new sensitive and specific tools for disease prognostication and management. Assessment of minimal residual disease (MRD) in response to therapy is one of these tools, as longer progression-free survival (PFS) is seen consistently among patients who have achieved MRD negativity. Current therapies lead to unprecedented frequency and depth of response, and next-generation flow and sequencing methods to measure MRD in bone marrow are in use and being developed with sensitivities in the range of 10-5 to 10-6 cells. These technologies may be combined with functional imaging to detect MRD outside of bone marrow. Moreover, immune profiling methods are being developed to better understand the immune environment in myeloma and response to immunomodulatory agents while methods for molecular profiling of myeloma cells and circulating DNA in blood are also emerging. With the continued development and standardization of these methodologies, MRD has high potential for use in gaining new drug approvals in myeloma. The FDA has outlined two pathways by which MRD could be qualified as a surrogate endpoint for clinical studies directed at obtaining accelerated approval for new myeloma drugs. Most importantly, better understanding of MRD should also contribute to better treatment monitoring. Potentially, MRD status could be used as a prognostic factor for making treatment decisions and for informing timing of therapeutic interventions. Clin Cancer Res; 23(15); 3980-93. ©2017 AACR.
포스터발표 : 그랜드볼룸 ; 한국인 자가면역간염-원발성 담즙성 간경변증 중복증후군의 진단과 특징 (초)
Authors: 변진명, 김상균, 김영석, 김희경, 정승원, 장재영, 이세환, 문종호, 김홍수, 이문성, 김부성
Journal: Clinical and Molecular Hepatology (2010)
TCTAP A-035 Invasive Versus Conservative Strategy in Non-ST-elevation Myocardial Infarction – Patient Characteristics, Outcomes and Reasons for Conservative Therapy: Data from a Single Tertiary Center
Authors: Billy Yonathan Wijaya, Nurun Nisa De Souza, Khung Keong Yeo
Journal: Journal of the American College of Cardiology (2017)
Next-generation in vivo optical imaging with short-wave infrared quantum dots
Authors: Oliver T. Bruns, Thomas S. Bischof, Daniel K. Harris, Daniel Franke, Yanxiang Shi, Lars Riedemann, Alexander Bartelt, Frank B. Jaworski, Jessica A. Carr, Christopher J. Rowlands, Mark W. B. Wilson, Ou Chen, He Wei, Gyu Weon Hwang, Daniel M. Montana, Igor Coropceanu, Odin B. Achorn, Jonas Kloepper, Joerg Heeren, Peter T. C. So, Dai Fukumura, Klavs F. Jensen, Rakesh K. Jain, Moungi G. Bawendi
Journal: Nature Biomedical Engineering (2017)